Ahmedabad – Cadila Pharmaceuticals, a pioneer in the pharmaceutical industry, proudly announces the launch of the world’s first aqueous formulation of cholecalciferol, setting a new benchmark in the treatment of Vitamin D deficiency. This ground-breaking innovation demonstrates superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to traditional oil-based cholecalciferol preparations available in the market.
Vitamin D deficiency is a major health concern globally, contributing significantly to the outcomes of various diseases. Cadila Pharmaceuticals’ innovative aqueous cholecalciferol injection offers a unique solution with rapid correction of Vitamin D deficiency in short span of time. This breakthrough not only enhances the efficacy of treatment but also ensures a painless and easy administration process, marking a significant advancement in patient care.
Key Features of Cadila Pharmaceuticals’ Aqueous Cholecalciferol Injection:
Superior Pharmacokinetics and Pharmacodynamics: The novel aqueous formulation demonstrates significant improvements in both pharmacokinetic and pharmacodynamics properties of the drug , outperforming conventional oil-based cholecalciferol preparations.
Rapid Correction of Vitamin D Deficiency: Patients can benefit from a swift correction of Vitamin D deficiency in short span of time, addressing a critical need for expedited treatment outcomes in many major illnesses.
Painless Administration: The injection is designed for ease of use, providing a painless experience for patients, promoting better compliance with treatment regimens.
Addressing Multifactorial Health Conditions:
The significance of Vitamin D extends well beyond bone health, influencing outcomes in various conditions such as Cardiovascular Disease, Diabetes Mellitus, and weakened immune systems. Vitamin D acts as an anti-hypertrophic agent, a stimulator of vascular smooth muscle cell proliferation, anti- fibrotic, antioxidant, anti-inflammatory, and an inhibitor of the Renin-Angiotensin-Aldosterone System (RAAS).
Cadila Pharmaceuticals recognizes the pivotal role Vitamin D plays in overall health and aims to revolutionize its treatment for better outcomes in multitude of major medical illnesses. By introducing the world’s first aqueous cholecalciferol injection, through totally indigenous research, the company envisions a paradigm shift in addressing Vitamin D deficiency globally.
Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals, stated, “Our commitment to innovation and patient centric research to bridge the gap in areas of unmet medical need has driven the development of this ground-breaking aqueous cholecalciferol injection. We believe this advancement will redefine the landscape of Vitamin D deficiency treatment and ensure better treatment outcomes,”
Dr. Vijayesh Gupta , COO- BSBU, Cadila Pharmaceuticals, added, “With the launch of the world’s first aqueous Vitamin D injection, Cadila Pharmaceuticals reaffirms its dedication to providing cutting-edge healthcare solutions. We anticipate this innovation will help clinicians to better design their treatment protocols for Vitamin D deficient patients and a large number of patients will benefit from the next generation, world’s first aqueous injectable Vitamin D.”
Cadila Pharmaceuticals invites healthcare professionals, patients, and stakeholders to explore this pioneering solution and join the journey towards a healthier and Vitamin D-replete future.
